KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Change in Receivables (2020 - 2025)

Historic Change in Receivables for Esperion Therapeutics (ESPR) over the last 6 years, with Q3 2025 value amounting to $11.2 million.

  • Esperion Therapeutics' Change in Receivables rose 5050.91% to $11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.2 million, marking a year-over-year increase of 10299.19%. This contributed to the annual value of $31.6 million for FY2024, which is 11434.47% up from last year.
  • According to the latest figures from Q3 2025, Esperion Therapeutics' Change in Receivables is $11.2 million, which was up 5050.91% from $26.5 million recorded in Q2 2025.
  • Esperion Therapeutics' Change in Receivables' 5-year high stood at $26.5 million during Q2 2025, with a 5-year trough of -$144000.0 in Q3 2021.
  • In the last 5 years, Esperion Therapeutics' Change in Receivables had a median value of $4.4 million in 2023 and averaged $5.6 million.
  • Its Change in Receivables has fluctuated over the past 5 years, first tumbled by 10501.39% in 2021, then skyrocketed by 263125.0% in 2022.
  • Esperion Therapeutics' Change in Receivables (Quarter) stood at $1.2 million in 2021, then soared by 83.01% to $2.2 million in 2022, then surged by 162.1% to $5.9 million in 2023, then surged by 109.81% to $12.3 million in 2024, then dropped by 8.8% to $11.2 million in 2025.
  • Its Change in Receivables stands at $11.2 million for Q3 2025, versus $26.5 million for Q2 2025 and $1.2 million for Q1 2025.